Cargando…

OM-85 is an immunomodulator of interferon-β production and inflammasome activity

The inflammasome–IL-1 axis and type I interferons (IFNs) have been shown to exert protective effects upon respiratory tract infections. Conversely, IL-1 has also been implicated in inflammatory airway pathologies such as asthma and chronic obstructive pulmonary disease (COPD). OM-85 is a bacterial e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dang, A. T., Pasquali, C., Ludigs, K., Guarda, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338315/ https://www.ncbi.nlm.nih.gov/pubmed/28262817 http://dx.doi.org/10.1038/srep43844

Ejemplares similares

Selective Activation of Human Dendritic Cells by OM-85 through a NF-kB and MAPK Dependent Pathway
por: Parola, Carmen, et al.
Publicado: (2013)

Effects of the Bacterial Extract OM-85 on Phagocyte Functions and the Stress Response
por: Baladi, S., et al.
Publicado: (1994)

Airway Administration of Bacterial Lysate OM-85 Protects Mice Against Respiratory Syncytial Virus Infection
por: Antunes, Krist Helen, et al.
Publicado: (2022)

Evidence that a primary anti-viral stimulation of the immune response by OM-85 reduces susceptibility to a secondary respiratory bacterial infection in mice
por: Rossi, Giovanni A., et al.
Publicado: (2018)

Broncho Vaxom (OM-85) modulates rhinovirus docking proteins on human airway epithelial cells via Erk1/2 mitogen activated protein kinase and cAMP
por: Roth, Michael, et al.
Publicado: (2017)

The inflammasome in biomaterial‐driven immunomodulation
por: Vasconcelos, Daniela P., et al.
Publicado: (2022)

Effect of OM-85 BV on reducing bronchiectasis exacerbation in Chinese patients: the iPROBE study
por: Gao, Jinming, et al.
Publicado: (2021)

Use of the Bacterial Lysate OM-85 in the Paediatric Population in Italy: A Retrospective Cohort Study
por: Cantarutti, Anna, et al.
Publicado: (2021)

Expert consensus on the role of OM-85 in the management of recurrent respiratory infections: A Delphi study
por: Esposito, Susanna, et al.
Publicado: (2022)

OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
por: Buendía, Jefferson Antonio, et al.
Publicado: (2022)

The OM-85 bacterial lysate: a new tool against SARS-CoV-2?
por: Pivniouk, Vadim, et al.
Publicado: (2023)

Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations
por: Choi, Joon Young, et al.
Publicado: (2023)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study
por: Bodemer, Christine, et al.
Publicado: (2017)

Bacterial lysates (OM-85 BV): a cost-effective proposal in order to contrast antibiotic resistance
por: TROIANO, GIANMARCO, et al.
Publicado: (2021)

IRF7-Associated Immunophenotypes Have Dichotomous Responses to Virus/Allergen Coexposure and OM-85-Induced Reprogramming
por: de Jong, Emma, et al.
Publicado: (2021)

Microbiota profiles in pre-school children with respiratory infections: Modifications induced by the oral bacterial lysate OM-85
por: Esposito, Susanna, et al.
Publicado: (2022)

Can bacterial lysates be useful in prevention of viral respiratory infections in childhood? The results of experimental OM-85 studies
por: Ballarini, Stefania, et al.
Publicado: (2022)

Prevention of respiratory tract infections with bacterial lysate OM-85 bronchomunal in children and adults: a state of the art
por: De Benedetto, Fernando, et al.
Publicado: (2013)

Clinical and Immunological Benefits of OM-85 Bacterial Lysate in Patients with Allergic Rhinitis, Asthma, and COPD and Recurrent Respiratory Infections
por: Koatz, Ana M., et al.
Publicado: (2016)

Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ()
por: Saravolac, E.G., et al.
Publicado: (1996)

Immunomodulators: interleukins, interferons, and IV immunoglobulin
por: Roelofs, Joris J., et al.
Publicado: (2008)

Protection against neonatal respiratory viral infection via maternal treatment during pregnancy with the benign immune training agent OM‐85
por: Lauzon‐Joset, Jean‐Francois, et al.
Publicado: (2021)

OM-85 BV for primary prevention of recurrent airway infections: a pilot randomized, double-blind, placebo-controlled study
por: de Souza, Fátima Cleonice, et al.
Publicado: (2020)

The Role of Interferons in Inflammation and Inflammasome Activation
por: Kopitar-Jerala, Nataša
Publicado: (2017)

To investigate the prevention of OM-85 on bronchiectasis exacerbations (iPROBE) in Chinese patients: study protocol for a randomized controlled trial
por: Gao, Jinming, et al.
Publicado: (2014)

Investigation of biofilm production and its association with genetic and phenotypic characteristics of OM (osteomyelitis) and non-OM orthopedic Staphylococcus aureus
por: Yu, Shengpeng, et al.
Publicado: (2020)

Identifying Organic Matter (OM) Types and Characterizing OM Pores in the Wufeng–Longmaxi Shales
por: Xie, Guoliang, et al.
Publicado: (2022)

Impact of OM-85 Given during Two Consecutive Years to Children with a History of Recurrent Respiratory Tract Infections: A Retrospective Study
por: Esposito, Susanna, et al.
Publicado: (2019)

Cost-effectiveness analysis of OM-85 vs placebo in the prevention of acute respiratory tract infections (ARTIs) in children that attend day-care centers
por: Berber, Arturo, et al.
Publicado: (2019)

OM-85 Broncho-Vaxom(®), a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells
por: Fang, Lei, et al.
Publicado: (2021)

Professor Om Prakash Sharma
por: Shrivastava, Nirbhay
Publicado: (2011)

Réunion de l'OMS
por: World Health Organization. Copenhagen. Regional Office for Europe
Publicado: (1986)

Florence Nightingale, O.M.
Publicado: (1910)

Motivatie om te bewegen
por: Rombout, Betty
Publicado: (2020)

The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression
por: Pivniouk, Vadim, et al.
Publicado: (2022)

Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
por: Dawson, Rod, et al.
Publicado: (2009)

The SARS-CoV-2 Entry Inhibition Mechanisms of Serine Protease Inhibitors, OM-85, Heparin and Soluble HS Might Be Linked to HS Attachment Sites
por: Cheudjeu, Antony
Publicado: (2022)

Immunomodulation of the NLRP3 Inflammasome through Structure-Based Activator Design and Functional Regulation via Lysosomal Rupture
por: Manna, Saikat, et al.
Publicado: (2018)

Evaluation of 400 m, 4.8 Gbit/s Versatile Link lengths over OM3 and OM4 fibres for the LHCb upgrade
por: Schwemmer, R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5of9ll9knnhk0n29qb3bprp149